CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • BTCY Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Reddit
  • 8-K Filing

Biotricity (BTCY) 8-KCompany’s Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise

Filed: 10 Sep 21, 3:03pm
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 8-K Current report
    • 99.1 Company’s Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise
    • Download Excel data file
    • View Excel data file
    BTCY similar filings
    • 7 Dec 21 Regulation FD Disclosure
    • 5 Nov 21 Biotricity Releases Fiscal 2022 Second Quarter Financial Results
    • 13 Sep 21 Biotricity Announces Closing of Exercise of Underwriter’s Option to Purchase Additional Common Stock
    • 10 Sep 21 Company’s Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise
    • 31 Aug 21 Biotricity Prices $15 Million Underwritten Public Offering of Common Stock and Listing on the Nasdaq Capital Market
    • 17 Aug 21 Biotricity Reports 290% Revenue Growth Year Over Year in Record First Quarter
    • 8 Jul 21 Biotricity’s 2021 Fiscal Fourth Quarter Growth Trend Continues into Fiscal 2022
    Filing view
    Share this filing

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(D) of The Securities Exchange Act Of 1934

     

    Date of report (Date of earliest event reported): September 8, 2021

     

    BIOTRICITY INC.
    (Exact name of registrant as specified in its charter)

     

    Nevada 000-56074 47-2548273

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    275 Shoreline Drive, Suite 150
    Redwood City, California 94065
    (Address of Principal Executive Offices)

     

    (650) 832-1626

    (Registrant’s telephone number, including area code)

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      
     Securities registered pursuant to Section 12(b) of the Act: None
      
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
      
     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

      
     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     

     

     

     
     

     

    Item 8.01. Other Events.

     

    On September 8, 2021, Biotricity Inc., a Nevada corporation (the “Company”), issued a press release announcing that its Chief Executive Officer Mr. Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m. ET on Monday, September 13, 2021. A copy of this press release is attached as Exhibit 99.1

     

    Item 9.01 Financial statements and Exhibits

     

    (d) Exhibits.

     

    Exhibit Number Description
    99.1 Press Release September 08, 2021
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: September 10, 2021

     

     BIOTRICITY INC.
      
     By:/s/ John Ayanoglou
      John Ayanoglou
      Chief Financial Officer

     

     

     

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn